MULTIPLE ORAL DOSES (ABT-229)/POSTPRANDIAL DIGESTIVE SYMPTOMS/DYSPEPSIA

多次口服剂量 (ABT-229)/餐后消化症状/消化不良

• 批准号: 6278443
• 负责人: MARK B SOSTEK
• 金额: $ 2.92万
• 依托单位: BOSTON UNIVERSITY MEDICAL CAMPUS
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6278443
• 关键词: clinical research; gastritis; gastrointestinal agents; gastrointestinal disorder chemotherapy; human subject; human therapy evaluation; oral administration

Functional or non ulcer dyspepsia is a upper gastrointestinal disorder that is characterized by persistent or recurrent symptoms of upper abdominal discomfort, which cannot be attributed to structural or biochemical abnormalities. The disorder is prevalent in approximately 25% of the population. This study is a phase II randomized double blind placebo-controlled multi center study of a new pro-motility agent (ABT-229) in patients with non ulcer dyspepsia.

功能性或非溃疡性消化不良是上消化道疾病 其特征在于持续或复发的上呼吸道症状， 腹部不适，不能归因于结构或 生化异常 这种疾病在大约25%的人中普遍存在 的人口。本研究是一项II期随机双盲研究， 一种新型促运动剂的安慰剂对照多中心研究 （ABT-229）治疗非溃疡性消化不良患者。